Fosfomycin/tobramycin

Fosfomycin/tobramycin (FTI)
Combination of
Fosfomycin Phosphonic acid
Tobramycin Aminoglycoside
Clinical data
Routes of
administration		 Inhalation

Fosfomycin/tobramycin is a formulation of fosfomycin and tobramycin. Fosfomycin is a phosphonic acid antibiotic active against gram-positive, gram-negative, and anaerobic bacteria. Tobramycin is an aminoglycoside with gram-negative activity. It is an inhaled medication targeting those with cystic fibrosis and is currently being studied by Gilead Sciences the United States Food and Drug Administration and the NIH General Clinical Research Center.[1]

See also

References

  1. ↑ Trapnell BC, McColley SA, Kissner DG, Rolfe MW, Rosen JM, McKevitt M, et al. (2011). "Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients with Pseudomonas Airway Infection.". Am J Respir Crit Care Med. 185 (2): 171–8. doi:10.1164/rccm.201105-0924OC. PMC 3361752Freely accessible. PMID 22095545.
This article is issued from Wikipedia - version of the 8/13/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.